Artificial intelligence techniques in liver cancer.

artificial intelligence deep learning diagnosis hepatocellular carcinoma liver cancer machine learning medical imaging prediction

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2024
Historique:
received: 11 04 2024
accepted: 15 08 2024
medline: 18 9 2024
pubmed: 18 9 2024
entrez: 18 9 2024
Statut: epublish

Résumé

Hepatocellular Carcinoma (HCC), the most common primary liver cancer, is a significant contributor to worldwide cancer-related deaths. Various medical imaging techniques, including computed tomography, magnetic resonance imaging, and ultrasound, play a crucial role in accurately evaluating HCC and formulating effective treatment plans. Artificial Intelligence (AI) technologies have demonstrated potential in supporting physicians by providing more accurate and consistent medical diagnoses. Recent advancements have led to the development of AI-based multi-modal prediction systems. These systems integrate medical imaging with other modalities, such as electronic health record reports and clinical parameters, to enhance the accuracy of predicting biological characteristics and prognosis, including those associated with HCC. These multi-modal prediction systems pave the way for predicting the response to transarterial chemoembolization and microvascular invasion treatments and can assist clinicians in identifying the optimal patients with HCC who could benefit from interventional therapy. This paper provides an overview of the latest AI-based medical imaging models developed for diagnosing and predicting HCC. It also explores the challenges and potential future directions related to the clinical application of AI techniques.

Identifiants

pubmed: 39290245
doi: 10.3389/fonc.2024.1415859
pmc: PMC11405163
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

1415859

Informations de copyright

Copyright © 2024 Wang, Fatemi and Alizad.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Lulu Wang (L)

Department of Engineering, School of Technology, Reykjavık University, Reykjavík, Iceland.
Department of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine and Science, Rochester, MN, United States.

Mostafa Fatemi (M)

Department of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine and Science, Rochester, MN, United States.

Azra Alizad (A)

Department of Radiology, Mayo Clinic College of Medicine and Science, Rochester, MN, United States.

Classifications MeSH